As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.”
All Velocity sites are fully prepared to support cell and gene therapy (CGT) clinical trials. With 220+ investigators, a global laboratory network, and sites with longstanding specialty research experience, Velocity can deliver patients for everything from large vaccine trials to focused cancer and rare disease trials involving genetically engineered therapies.
Read the full press release: https://www.advarra.com/about-advarra/news/the-largest-cell-and-gene-therapy-site-network-now-includes-1500-members/
